Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies
Pharma Looks to Inflammasome Inhibitors as All-Around Therapies

Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.

Many major biopharmaceutical companies are developing or acquiring drugs that target the NLRP3 inflammasome, a large intracellular complex that researchers say can spark inflammation and stoke diseases of lifestyle and aging.

drug development
Securing the Antibody Supply Chain through Recombinant Antibody Technology: A COVID-19 Case Study
Securing the Antibody Supply Chain through Recombinant Antibody Technology: A COVID-19 Case Study
The Scientist Creative Services Team in collaboration with Sartorius Corporation | Mar 29, 2021
Nicholas Hutchings will discuss how recombinant antibody technology can speed up the response to a pandemic.
Fast-Tracking COVID-19 Research
Fast-Tracking COVID-19 Research
The Scientist Creative Services Team in collaboration with Sartorius Corporation | Mar 17, 2021
Identifying molecular targets for SARS-CoV-2 therapeutics.
Eli Lilly Claims New Drug Can Slow Alzheimer’s-Related Decline
Eli Lilly Claims New Drug Can Slow Alzheimer’s-Related Decline
Lisa Winter | Mar 16, 2021
Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.
Gene Therapy for Sickle Cell Not Linked to Cancer, Bluebird Finds
Gene Therapy for Sickle Cell Not Linked to Cancer, Bluebird Finds
Lisa Winter | Mar 11, 2021
Clinical trials were halted after the treatment’s vector that ferries in the healthy genetic sequence was identified in the genome of a patient’s cancer cells.
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Regeneron Cocktail Stumbles Against SARS-CoV-2 Variant in Vitro
Marcus A. Banks | Mar 1, 2021
A treatment of two monoclonal antibodies against SARS-CoV-2 is ninefold less effective in the lab against the B.1.351 variant than against the dominant version of the virus.
Questions Raised About Widely Used Blood-Brain Barrier Model
Questions Raised About Widely Used Blood-Brain Barrier Model
Catherine Offord | Feb 16, 2021
A study has sparked controversy by suggesting that cells made using a popular lab protocol have been misidentified, with potentially serious repercussions for brain research. Critics say the significance of the findings has been overstated.
<em>Spectrum</em> Reporting Prompts New Review of Common Drug
Spectrum Reporting Prompts New Review of Common Drug
Jaclyn Jeffrey-Wilensky | Feb 11, 2021
The review of more than two dozen studies finds aripiprazole has side effects and does not change core autism features, but parents report improvements in self-injury, tantrums, and other challenging behaviors.
Vaccines Versus the Mutants
Vaccines Versus the Mutants
Anthony King | Feb 8, 2021
Facing new variants of SARS-CoV-2, some vaccines may offer more robust protection or be more easily redesigned to target them.
One-Shot COVID-19 Vaccine Prevents Severe Disease
One-Shot COVID-19 Vaccine Prevents Severe Disease
Asher Jones | Jan 29, 2021
Johnson & Johnson’s vaccine is less effective at preventing COVID-19 than other approved vaccines are, but experts say it could still be an important tool in curbing the pandemic.